Free Trial
NYSE:KVUE

Kenvue Q3 2026 Earnings Report

Kenvue logo
$17.62 +0.04 (+0.20%)
As of 01:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kenvue EPS Results

Actual EPS
N/A
Consensus EPS
$0.28
Beat/Miss
N/A
One Year Ago EPS
N/A

Kenvue Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.86 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kenvue Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Friday, November 6, 2026
Conference Call Time
12:30PM ET

Conference Call Resources

Kenvue Earnings Headlines

Kenvue Inc. (NYSE:KVUE) Stock Rated "Hold" by Wall Street Brokerages
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
Kenvue (KVUE), Why Is It Drawing Fresh Attention Now?
See More Kenvue Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kenvue? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kenvue and other key companies, straight to your email.

About Kenvue

Kenvue (NYSE:KVUE) (NYSE: KVUE) is a consumer health company that develops, markets and sells self-care, skin health and essential health products. Its portfolio includes over-the-counter medicines, allergy and cold remedies, pain-relief products, oral-care items, wound-care products, baby care products and beauty brands.

Kenvue’s principal brands include Tylenol, Motrin, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s and BAND-AID. The company distributes its products through pharmacies, retailers, e-commerce channels, healthcare providers and other commercial outlets in markets around the world.

Kenvue was formed through the separation of Johnson & Johnson’s consumer health business and became an independent publicly traded company in 2023. The company is headquartered in Skillman, New Jersey, and serves consumers across a broad range of geographic markets. Its leadership is focused on expanding its established brand portfolio and developing consumer health products intended for everyday use.

View Kenvue Profile